{"entity":{"id":"nct07543055","kind":"trial","name":"A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread","aka":[],"tldr":"A phase 1 trial of BPX-601 run by Regeneron Pharmaceuticals, now recruiting.","summary":"A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread is a phase 1 interventional study registered as NCT07543055 by Regeneron Pharmaceuticals, with 36 participants planned, started 2026-09-08. Conditions recorded: Prostate Cancer. Interventions recorded: BPX-601.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07543055","url":"https://clinicaltrials.gov/study/NCT07543055"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["bpx-601"],"companies":["bellicum","regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07543055","phase":"1","setting":"A Phase 1, Open-Label, Dose-Escalation Study of BPX-601, an Anti-PSCA CAR T Cell Drug Product, in Relapsed/Refractory Metastatic Castration-Resistant Prostate Cancer","sponsor":"Regeneron Pharmaceuticals","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07543055/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"bpx-601","kind":"drug","name":"BPX-601","route":"/drugs/bpx-601/"}],"company":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}